SCHEMBL17332078

SCHEMBL17332078

O=C1CCCc2ccc(OCc3cc(Cl)ccc3OS(=O)(=O)C(F)(F)F)cc21

nearest known ligand 0.57

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ MAOA P21397 18/20 0.57
▸ MAOB P27338 18/20 0.57
▸ HPD P32754 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17332121 0.88 MAOA (0.51) MAOAMAOBHPD
SCHEMBL17332123 0.80 MAOA (0.71) MAOAMAOBHPD
SCHEMBL1513290 0.79 MAOA (0.53) MAOAMAOB
SCHEMBL29726325 0.79 MAOA (0.70) MAOAMAOBHPD
SCHEMBL6121177 0.79 MAOA (0.70) MAOAMAOBHPD
SCHEMBL17332114 0.78 MAOA (0.68) MAOAMAOBHPD
SCHEMBL8520565 0.76 MAOA (0.50) MAOAMAOB
SCHEMBL8520563 0.76 MAOA (0.50) MAOAMAOB
SCHEMBL6309072 0.74 MAOB (1.00) MAOAMAOBHPD
SCHEMBL1513396 0.72 MAOB (0.46) MAOAMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11192875-B2 Processes for preparing antiviral compounds GILEAD PHARMASSET LLC (US) 2021-12-07 — — US disclosed
US-20200392100-A1 PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2020-12-17 — — US disclosed
US-10584109-B2 Processes for preparing antiviral compounds Gillead Pharmasset LLC (US) 2020-03-10 — — US disclosed
US-20190263771-A1 PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2019-08-29 — — US disclosed
US-20180179175-A1 PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS GILEAD PHARMASSET LLC 2018-06-28 — — US disclosed
US-9890134-B2 Processes for preparing antiviral compounds GILEAD PHARMASSET LLC (US) 2018-02-13 — — US disclosed
US-20170283390-A1 PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2017-10-05 — — US disclosed
US-9670187-B2 Processes for preparing antiviral compounds GILEAD PHARMASSET LLC (US) 2017-06-06 — — US disclosed
EP-3154984-A1 PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS Gilead Pharmasset LLC (US) 2017-04-19 — — EP disclosed
US-20150361073-A1 PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2015-12-17 — — US disclosed
WO-2015191437-A1 PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS GILEAD PHARMASSET LLC (US) 2015-12-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10584109-B2 Processes for preparing antiviral compounds MAVS, EIF2AK2, SAMHD1 MAOA 1588/4885MAOB 1117/4885HPD 2552/4885
US-11192875-B2 Processes for preparing antiviral compounds MAVS, EIF2AK2, SAMHD1 MAOA 1588/4885MAOB 1117/4885HPD 2552/4885
US-20170283390-A1 PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, SAMHD1 MAOA 1588/4885MAOB 1117/4885HPD 2552/4885
US-20150361073-A1 PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, SAMHD1 MAOA 1588/4885MAOB 1117/4885HPD 2552/4885
US-20180179175-A1 PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, SAMHD1 MAOA 1588/4885MAOB 1117/4885HPD 2552/4885
US-20200392100-A1 PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, SAMHD1 MAOA 1588/4885MAOB 1117/4885HPD 2552/4885
US-20190263771-A1 PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, SAMHD1 MAOA 1588/4885MAOB 1117/4885HPD 2552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback